Previous Close | 0.4111 |
Open | 0.4160 |
Bid | 0.4213 x 800 |
Ask | 0.4500 x 1100 |
Day's Range | 0.4060 - 0.4559 |
52 Week Range | 0.3100 - 0.7500 |
Volume | |
Avg. Volume | 318,607 |
Market Cap | 25.654M |
Beta (5Y Monthly) | -0.36 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6400 |
Earnings Date | Aug 13, 2024 - Aug 19, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.58 |
Live video webcast on Monday, June 17th at 1:00 PM ETOCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Conference on Monday, June 17, 2024 at 1:00 PM ET. As part of the event, Mr. Equels will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested partie
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ETOCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series on Wednesday, June 5, 2024 at 12:00 PM ET. As part of the event, Mr. Equels will provide a corporate overview and business outlook. I
OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class A warrants to purchase up to an aggregate of 5,640,958 shares of common s